SCHEMBL2599764

SCHEMBL2599764

COC(=O)c1cc(Cl)c2c(c1)C1(CC1)CC(C)(C)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.38
AKR1B1 P15121 1/20 0.36
ALDH1A1 P00352 5/20 0.36
HTT P42858 2/20 0.36
CYP3A4 P08684 3/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
CA14 Q9ULX7 1/20 0.34
RARB P10826 2/20 0.33
RARG P13631 2/20 0.33
KDM4E B2RXH2 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
NFKB1 P19838 1/20 0.33
XDH P47989 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14702612 0.85 AKR1B1 (0.39) AKR1B1CYP26A1
SCHEMBL2599767 0.76 RARB (0.44) PDK2AKR1B1ALDH1A1CYP3A4CA12
SCHEMBL7155489 0.71 PDK2 (0.39) PDK2ALDH1A1HTTCYP3A4CA12
SCHEMBL2240208 0.66 ALDH1A1 (0.43) PDK2ALDH1A1HTTCA12CA1
SCHEMBL8336066 0.65 CA1 (0.56) PDK2ALDH1A1HTTCYP3A4CA12
SCHEMBL21792150 0.64 NOTUM (0.44) PDK2ALDH1A1HTTCYP3A4CA12
SCHEMBL522606 0.63 CA1 (0.54) PDK2ALDH1A1HTTCA12CA1
SCHEMBL282150 0.63 KDM4E (0.63) ALDH1A1HTTCA12CA1CA2
SCHEMBL31147105 0.63 CA1 (0.54) PDK2ALDH1A1HTTCYP3A4CA12
SCHEMBL3555140 0.63 CA1 (0.54) PDK2ALDH1A1HTTCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571356-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2013-03-27 EP disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP 2013-02-14 US disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed
WO-2011146324-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130040978-A1 SPIRO ISOXAZOLINE COMPOUNDS AS SSTR5 ANTAGONISTS SSTR5, SSTR2, SSTR1 PDK2 128/4885AKR1B1 508/4885ALDH1A1 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.